Tabla de contenido
Idiomas disponibles
Idiomas disponibles
Specimen
Clinical
Type
Site
Prevalence
1
24.1%
2
22.4%
12
MS
4
23.8%
5
15.5%
7
0.0%
1
24.1%
2
22.4%
13
MNU
4
23.8%
5
15.5%
7
0.0%
1
24.1%
2
22.4%
14
MUPT
4
23.8%
5
15.5%
7
0.0%
8
22 of the 115 FS PIS positive subjects were co-infected with GC.
9
22 of the 115 FV PIS positive subjects were co-infected with GC.
10
22 of the 115 FNU positive subjects were co-infected with GC.
11
22 of the 115 FUPT positive subjects were co-infected with GC.
12
33 of the 101 MS positive subjects were co-infected with GC.
13
33 of the 101 MNU positive subjects were co-infected with GC.
14
33 of the 101 MUPT positive results were co-infected with GC.
n
Sensitivity
95% C.I.
87.8%
203
(75.2% – 95.4%)
(43/49)
100.0%
76
(80.5% – 100.0%)
(17/17)
95.8%
101
(78.9% – 99.9%)
(23/24)
90.9%
71
(58.7% – 99.8%)
(10/11)
21
NA
98.0%
203
(89.1% – 99.9%)
(48/49)
100.0%
76
(80.5% – 100.0%)
(17/17)
95.8%
101
(78.9% – 99.9%)
(23/24)
100.0%
71
(71.5% – 100.0%)
(11/11)
21
NA
98.0%
203
(89.1% – 99.9%)
(48/49)
100.0%
76
(80.5% – 100.0%)
(17/17)
95.8%
101
(78.9% – 99.9%)
(23/24)
100.0%
71
(71.5% – 100.0%)
(11/11)
21
NA
Specificity
98.1%
(151/154)
98.3%
(90.9% – 100.0%)
(58/59)
100.0%
(95.3% – 100.0%)
(77/77)
96.7%
(58/60)
100.0%
NA
(83.9% – 100.0%)
(21/21)
99.4%
(96.4% – 100.0%)
(153/154)
100.0%
(93.9% – 100.0%)
(59/59)
98.7%
(93.0% – 100.0%)
(76/77)
98.3%
(91.1% – 100.0%)
(59/60)
100.0%
NA
(83.9% – 100.0%)
(21/21)
98.1%
(151/154)
96.6%
(57/59)
98.7%
(93.0% – 100.0%)
(76/77)
98.3%
(91.1% – 100.0%)
(59/60)
100.0%
NA
(83.9% – 100.0%)
(21/21)
16
# CT
(+)
and
95% C.I.
GC (+) PPV%
(94.4% – 99.6%)
9
10
11 100.0% 98.7%
(88.5% – 99.6%)
3
0
9
10 100.0% 100.0%
11
3
0
(94.4% – 99.6%)
9
(88.3% – 99.6%)
10
11
3
0
NPV%
93.5% 96.2%
94.4% 100.0%
83.3% 98.3%
NA
NA
98.0% 99.4%
95.8% 98.7%
91.7% 100.0%
NA
NA
94.1% 99.3%
89.5% 100.0%
95.8% 98.7%
91.7% 100.0%
NA
NA
Capítulos
Tabla de contenido
